A multi-institutional cohort study of 278 patients with unresectable or recurrent GC treated with nivolumab showed that CRP levels ≤ 0.5 mg/dL (HR, 0.476, 95% CI 0.336–0.675, p < 0.001) and albumin levels >3.5 g/dL (HR, 0.688; 95% CI, 0.478–0.991, p = 0.045) were independently associated with improved outcomes in multivariate analysis [34]. This evidence concerns the gene CRP and gastric cancer.